FIELD: biotechnology.
SUBSTANCE: invention relates to a population of insulin-producing cells containing: insulin-positive and NKX6.1-positive cells in amount of 30 to 50%; insulin-positive and NKX6.1-negative cells in amount of 20 to 32%; and Ki67-positive cells in an amount of less than 3%, as well as to a drug containing it. Also disclosed is a method of producing insulin-producing cells, involving culturing pluripotent stem cells in presence of 5–50 ng/ml of activin A to obtain definitive endoderm cells, induction of differentiation of definitive endoderm cells into endocrine precursor cells and culturing endocrine precursor cells in a medium containing an FGFR1 inhibitor to obtain insulin-producing cells, and a method of creating pancreatic islet cells is also disclosed, where the method involves transplantation of insulin-producing cells into a living body to cause differentiation into pancreatic islet cells.
EFFECT: invention is effective for treating diabetes mellitus, for improving fasting or postprandial glucose levels in a patient, as well as for reducing a risk of hypoglycaemia in a patient suffering diabetes mellitus.
23 cl, 9 dwg, 7 tbl, 5 ex
